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Purpose: Presently, 22 genes have been described in association with autosomal dominant retinitis pigmentosa (adRP);
however, they explain only 50% of all cases, making genetic diagnosis of this disease difficult and costly. The aim of this
study was to evaluate a specific genotyping microarray for its application to the molecular diagnosis of adRP in Spanish
patients.
Methods: We analyzed 139 unrelated Spanish families with adRP. Samples were studied by using a genotyping microarray
(adRP). All mutations found were further confirmed with automatic sequencing. Rhodopsin (RHO) sequencing was
performed in all negative samples for the genotyping microarray.
Results: The adRP genotyping microarray detected the mutation associated with the disease in 20 of the 139 families with
adRP. As in other populations, RHO was found to be the most frequently mutated gene in these families (7.9% of the
microarray genotyped families). The rate of false positives (microarray results not confirmed with sequencing) and false
negatives (mutations in RHO detected with sequencing but not with the genotyping microarray) were established, and
high levels of analytical sensitivity (95%) and specificity (100%) were found. Diagnostic accuracy was 15.1%.
Conclusions: The adRP genotyping microarray is a quick, cost-efficient first step in the molecular diagnosis of Spanish
patients with adRP.
Retinitis pigmentosa (RP, OMIM 268000) is the most
common form of inherited retinopathy, with a prevalence of
approximately one in 4,000 [1]. RP is a group of clinically and
genetically  heterogeneous  retinal  degenerative  diseases
characterized  by  progressive  loss  of  photoreceptors  and
pigment deposits predominantly in the peripheral retina and
by a relative sparing of the central retina. The diagnostic
criteria for RP were established by Marmor [2-5]. To date, 56
genes  have  been  associated  with  non-syndromic  RP
(RetNet), and all modes of inheritance have been described in
this  disease  (autosomal  dominant,  autosomal  recessive,  X
linked, and in rare cases, digenic) [6].
Autosomal  dominant  RP  (adRP)  accounts  for
approximately 15% of Spanish families with RP [7,8]. The
large number of genes involved in adRP complicates genetic
analysis  in  these  patients.  To  date,  22  genes  have  been
associated with adRP (RetNet):
Bestrophin  (BEST1,  11q12.3),  carbonic  anhydrase  IV
(CA4, 17q23), cone-rod homeobox (CRX, 19q13.3), fascin
homolog 2 (FSCN2, 17q25), guanylate cyclase activator 1B
(GUCA1B,  6p21.1),  inosine  5′-monophosphate
dehydrogenase  1(IMPDH1,  7q32.1),  kelch-like  7
(Drosophila; KLHL7, 7p15.3), nuclear receptor subfamily 2,
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group E, member 3 (NR2E3, 15q22.32), neural retina leucine
zipper (NRL, 14q11.2), PRP3 pre-mRNA processing factor 3
homolog (S. cerevisiae; PRPF3, 1q21.1), PRP6 pre-mRNA
processing  factor  6  homolog  (S.  cerevisiae;  PRPF6,
20q13.33), PRP8 pre-mRNA processing factor 8 homolog (S.
cerevisiae; PRPF8,17q13.3), PRP31 pre-mRNA processing
factor  31  homolog  (S.  cerevisiae;  PRPF31,  19q13.4),
peripherin 2 (RDS / PRPH2, 6q21.2), retinol dehydrogenase
12  (all-trans/9-cis/11-cis)  (RDH12,  14q24.1),  rhodopsin
(RHO, 3q21–24), retinal outer segment membrane protein 1
(ROM1, 11q13), retinitis pigmentosa 1 (RP1, 8q11.3), retinitis
pigmentosa 9 (RP9, 7p14.3), sema domain, immunoglobulin
domain  (Ig),  transmembrane  domain  (TM)  and  short
cytoplasmic  domain,  (semaphorin)  4A  (SEMA4A,  1q22),
small nuclear ribonucleoprotein 200 kDa (U5) (SNRNP200,
2q11.2) and topoisomerase I binding, arginine/serine-rich, E3
ubiquitin  protein  ligase  (TOPORS,  9q21.1).  Patients  with
adRP, from informative families, are studied with linkage
analysis,  or  gene-by-gene,  according  to  their  established
prevalence in the analyzed population. This method is costly,
requires substantial human resources, and is time-consuming.
However,  only  around  15%–60%  of  adRP  cases  can  be
explained  by  mutations  in  these  genes  [8-12],  and  the
detection ratio depends on the population studied and the
analytical technique [8-12], thus making molecular diagnosis
and prognosis more difficult and complex.
The aim of this study was to evaluate a specific adRP
genotyping microarray (Asper Biotech, Ltd., Tartu, Estonia)
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1478for application to the molecular diagnosis of Spanish families
with adRP. We selected and analyzed, using the genotyping
microarray, 139 Spanish families with clinical diagnosis of
RP as well as pedigree evidence indicating the autosomal
dominant  mode  of  inheritance  (according  to  previously
established criteria [7,8]).
METHODS
Patients: We studied the molecular causes of the disease in
139 unrelated Spanish families with adRP recruited from 1990
to  May  2011.  Seventy-eight  of  these  families  had  been
previously  screened  for  CRX  (Chromosome  19q13.3),
FSCN2 (17q25), IMPDH1 (7q32.1), NRL (14q11.2), PRPF3
(1q21.1),  PRPF8  (17q13.3),  PRPF31  (19q13.4),  RDS
(6q21.2), RHO (3q21–24), ROM1 (11q13), and RP1 (8q11.3),
with  other  molecular  methods  (denaturing  gradient  gel
electrophoresis and sequencing verification), with negative
results, and 61 had had no prior testing.
The  adRP  diagnosis  was  based  on  ophthalmologic
examination and pedigree data. We classified our patients as
affected by RP according to the following clinical criteria:
night  blindness,  progressive  loss  of  peripheral  vision
(midperipheral scotoma or ring scotoma), fundus compatible
with RP (with altered retinal pigment epithelium, black bone
spicule-like pigmentation, pallor of the optic nerve head, and
retinal vessel attenuation), and pathologic electroretinogram
showing a marked reduction in rod or rod and cone signaling
[2-5].  Autosomal  dominant  inheritance  was  assessed
according to previously established criteria [7,8], either the
presence of three or more generations, with both men and
women among all affected family members, or at least two
affected generations with male-to-male transmission; these
requirements reduced the likelihood of including X-linked
families in our study.
Informed consent was obtained from all persons involved
in the study, and research protocols were approved by the
Bioethical Committee, of the IIS-Fundación Jiménez Díaz, in
accordance with the tenets of the Declaration of Helsinki.
One affected member of each family was analyzed using
the  adRP  genotyping  microarray.  Whenever  a  sequence
change was detected and confirmed, the study was extended
to the rest of the family.
Screening for mutations: DNA was extracted from peripheral
blood samples collected in EDTA tubes using an automated
DNA extractor according to the manufacturer’s instructions
(model BioRobot EZ1; Qiagen, Hilden, Germany).
We first used a specific adRP genotyping microarray for
mutation screening [13] (ADRP genetest). This genotyping
microarray is based on Arrayed Primer Extension (APEX)
technology. We used two versions of the array. The first
version was used from October 2007 to September 2009, and
contained  353  disease-associated  sequence  variants  in  13
adRP  genes  (CA4,  FSCN2,  IMPDH1,  NRL,  PRPF3,
PRPF31, PRPF8, RDS, RHO, ROM1, RP1, RP9, and CRX).
The second version was used from September 2009 to June
2011, and had 386 disease-associated sequence variants in 16
adRP genes (NR2E3, KLHL7, and TOPORS were added to the
previous  13  genes,  one  mutation  for  each  gene).  Direct
sequencing, using the BigDye Terminator Cycle Sequencing
v3.1 kit (Applied Biosystems, Carlsbad, CA) and analyzing
purified sequencing reactions in an ABI PRISM 3730 DNA
analyzer  (Applied  Biosystems),  was  used  to  confirm  the
results  obtained  with  the  genotyping  microarray  and  to
segregate the disease-causing mutations in the families (all
mutations detected, segregated with the disease).
Additionally, in uncharacterized families analyzed before
2009, missense mutation p.Gly56Arg in the NR2E3 gene was
analyzed as previously reported [14] until it was introduced
in the microarray in September 2009. As RHO is the most
mutated gene among Spanish patients with adRP [9], analysis
of  all  five  exons  of  the  RHO  gene  was  performed  using
intragenic  primers,  as  previously  described  [15],  for  all
negative array results to detect false negatives.
Statistical analysis: Specificity and sensitivity calculations
were performed using the free software package Epidat 4.0
(Organización Panamericana de la Salud y Consellería de
Sanidade de la Xunta de Galicia, 2011). Differences in the
detection ratio were analyzed using the χ2 test included in
Epidat 4.0.
RESULTS
Using  the  adRP  genotyping  microarray,  we  detected  the
mutation associated with the disease in 21 of the 139 families
with  adRP  (15.1%).  There  were  no  false  positives,  as  all
mutations  previously  detected  with  the  adRP  genotyping
microarray were confirmed and segregated with sequencing
analysis. One false negative, for the p.Glu181Lys mutation in
RHO (the mutation included in the microarray), was detected
after RHO sequencing. This gives us an array sensitivity not
higher than 95%, as the mutations in other genes (not RHO)
present in the array were not sequenced on negative samples,
and specificity of 100% for the spots present in the microarray.
The microarray detected mutations in ten patients out of
the 78 previously studied families (12.8%) and in 10 of the 61
(16.4%) of the families analyzed for the first time. There was
no statistical difference in the detection ratio between both
groups (p=0.28).
Additionally, previously studied families with negative
results underwent analysis of the p.Gly56Arg mutation in
NR2E3, before it was included in the microarray. The analysis
of this mutation allowed us to characterize five more adRP
families.
The  sequencing  of  RHO  in  those  patients  who  were
negative according to the adRP genotyping microarray testing
(119) allowed us to characterize one additional family.
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tested population, 21 of which were detected with genotyping
microarray and six with direct sequencing. The genes in which
mutations were found are RHO, NR2E3, PRPF31, RP1, and
CRX. Eleven of the families with mutations had a mutation in
RHO: ten were detected with the microarray and one with
direct sequencing. Six families presented with the p.Gly56Arg
mutation in NR2E3 (one detected with the adRP genotyping
microarray  and  five  with  direct  sequencing  before  the
mutation was included in the microarray). The other mutations
were all detected with the microarray: four in PRPF31, three
in RP1, and one in CRX. Table 1 shows the distribution of the
mutations around the adRP genes in the cohort of Spanish
families  studied.  Figure  1  shows  the  frequency  of  adRP
mutations detected with microarray genotyping in our cohort
of adRP families (n=139).
DISCUSSION
Although several studies have been published on the use of
this  kind  of  genotyping  microarray  for  molecular
characterization of other retinal dystrophies (Stargardt disease
[16,17], Leber congenital amaurosis [18,19], Usher syndrome
[20,21], and autosomal recessive RP [22]), this is the first
study to be published on the sensitivity and specificity of the
adRP  genotyping  microarray  for  application  to  molecular
diagnosis of patients with adRP.
In this study, we performed a molecular analysis of 139
Spanish  families  with  adRP  with  the  adRP  genotyping
microarray,  and  in  all  the  cases,  sequencing  analysis
confirmed  the  mutation  previously  detected  with  the
genotyping microarray.
With the subsequent sequencing analysis of the NR2E3
dominant  mutation  (in  those  who  were  negative  for
microarray testing), we identified the causative gene in 17.4%
of the families studied. In our cohort of patients, we detected
26  different  mutations,  13  in  more  than  one  family:
p.Gly56Arg in the NR2E3 gene (in six families), p.Pro347Leu
in  the  RHO  gene  (in  four  families),  and  p.Thr94Met  in
PRPF31 (in three families). In Spanish families, the mutation
p.Gly56Arg in the NR2E3 gene is the most common single
mutation detected in our patients with adRP, representing 10%
(6/60)  of  the  total  of  our  mutated  families  (four  of  these
families reside in the same small city in Spain, and a further
study to find a common ancestor is under way).
Interestingly, although mutations in RHO are the most
commonly  associated  cause  of  adRP  according  to  other
TABLE 1. MUTATIONS DETECTED IN THE ADRP SPANISH COHORT (N=139)
Gene Mutation Number of mutated families
RHO
  p.Gly106Arg 1
  p.Arg135Leu 1
  p.Ala164Glu 1
  p.Pro171Leu 1
  p.Tyr178Cys 1
  p.Glu181Lys 1*
  p.Gly182Ser 1
  p.Asp190Tyr 1
  p.Pro347Leu 4
RP1
  p.Arg677Stop 1
  p.Lys705fsX711 1
  p.Cys744Stop 1
PRPF31
  p.Cys299Arg 1
  p.Thr494Met 3
CRX
  p.Arg41Gln 1
NR2E3
  p.Gly56Arg 1 (microarray genotyping) +
    5 (direct sequencing)
Total   20 (microarray genotyping) + 6 (direct
sequencing)
          *Detected by direct sequencing, microarray genotyping false negative.
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responsible for 7.9% of the total families studied. This could
be because not all reported mutations for RHO are included
in the microarray. In fact, in all of our families (data not
shown) RHO accounts for 53.3% of all mutated families, 32
out of 60, from which 21 were diagnosed with denaturing
gradient  gel  electrophoresis  with  sequencing  confirmation
[25,26]  before  the  introduction  of  the  adRP  genotyping
microarray (20 of those mutations are actually included in the
array), and 18.6% of all the families with adRP (32 out of 172).
Fifty-seven of the 60 mutations found in RHO are present in
the  adRP  genotyping  microarray;  therefore,  analyzing  the
diagnostic  accuracy  of  a  protocol  for  adRP  including
genotyping microarray followed by RHO sequencing would
be  interesting,  as  RHO  is  the  most  mutated  gene  among
Spanish patients with adRP [9] and a considerable percentage
of mutations are not covered by the array (5%).
In other populations, mutations in known adRP genes are
estimated to account for at least 50%–60% of adRP cases
[9-12], although recurrent mutations (p.Pro23His in RHO, c.
828+3A>T in RDS, and p.Leu762fsX and p.Arg677X777 in
RP1) account for around 35% of all cases, and novel mutations
are found in the others [12]. In our study, only three mutations
are  recurrent,  accounting  for  65%  (13/20)  of  the  total
mutations detected with the microarray.
Our  results  show  the  adRP  genotyping  microarray  is
useful as the first step in molecular diagnosis of Spanish
families with adRP. This technology provided a quick and
cost-effective method for performing the previously described
adRP-causative mutation analysis. The diagnostic accuracy of
adRP genotyping microarray in this study was 14.4%, but the
most  recent  version  of  the  microarray  also  contains  the
mutation  p.Gly56Arg  in  the  NR2E3  gene,  which,  in  this
cohort, would have allowed diagnosis in 18% of the families
(25 out of 139). The adRP genotyping microarray for genetic
diagnosis of families with autosomal dominant RP could be
used as the first step to diagnose them, though the microarray
must be updated periodically due to the discovery of new
genes and mutations responsible for adRP. The microarray
could  also  be  used  as  the  second  step  for  previously
uncharacterized families. The adRP genotyping microarray is
an efficient approach for adRP diagnosis, although families
uncharacterized with the adRP genotyping microarray must
undergo  complementary  analysis  to  continue  research  to
identify  new  disease-causing  mutations  in  the  genes
associated with adRP.
Identifying the underlying disease-causing mutation in
families with adRP is an essential step in diagnosis and genetic
counseling. Moreover, faster detection of the mutations of this
disease  will  allow  patients  earlier  access  to  gene-based
therapy when it is developed.
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